Clinical Trials
12 trialsNCT04527991 2026-06-02
TROPiCS-04
Gilead Sciences
Phase 3 Completed
NCT06524544 2026-06-02
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT04579224 2026-05-29
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT07461454 2026-05-26
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Recruiting
NCT06801834 2026-05-20
EVOKE-SCLC-04
Gilead Sciences
Phase 3 Recruiting
NCT06431633 2026-05-18
ARIAN
Fundación GECP
Phase 3 Recruiting
NCT05089734 2026-05-07
EVOKE-01
Gilead Sciences
Phase 3 Active not recruiting
NCT07178730 2026-05-06
ADAPT-TN-IV
West German Study Group
Phase 3 Not yet recruiting
NCT05633654 2026-04-30
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Gilead Sciences
Phase 3 Recruiting
NCT04595565 2026-04-22
SASCIA
GBG Forschungs GmbH
Phase 3 Active not recruiting
NCT07533123 2026-04-16
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3 Recruiting
NCT05382299 2026-04-06
ASCENT-03
Gilead Sciences
Phase 3 Active not recruiting